Latest News and Press Releases

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (Nasdaq: MNKD), announced today that its first quarter 2025 financial results will be released...

MANNKIND TEAMS UP WITH JUNCOS HOLLINGER RACING (JHR) DRIVER CONOR DALY TO DRIVE AWARENESS OF DIABETES AND INNOVATIVE TREATMENT OPTIONS

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MANNKIND CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), will release its 2024 fourth quarter and full year financial results after market...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...

Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind...

MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH